Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + ketamine is a multimodal analgesic combination consisting of the synthetic opioid fentanyl and the dissociative anesthetic ketamine. Fentanyl is a potent mu-opioid receptor agonist that provides rapid and effective pain relief but is associated with side effects such as respiratory depression and nausea. Ketamine acts primarily as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, providing analgesia and anesthesia while maintaining respiratory drive and hemodynamic stability. In clinical practice, particularly in bariatric and ambulatory surgeries, the combination is utilized to achieve an "opioid-sparing" effect, reducing the total dose of narcotics required for postoperative pain management and potentially improving recovery outcomes in high-risk populations like those with obstructive sleep apnea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + ketamine.